Alopecia and Hair Loss: Dermatological Causes and Options

Hair loss affects an estimated 80 million people in the United States, according to the American Academy of Dermatology (AAD), making it one of the most common reasons patients seek dermatological evaluation. The term "alopecia" encompasses a clinically diverse spectrum of conditions — from genetically programmed follicle miniaturization to immune-mediated destruction of hair follicles — each with distinct mechanisms, prognoses, and management pathways. This page provides a structured reference covering the dermatological classification, causal drivers, diagnostic considerations, and major treatment categories relevant to hair loss, situated within the regulatory and clinical frameworks that govern dermatological care in the United States. Broader context on how dermatology is regulated is available at Regulatory Context for Dermatology.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix
• References

Definition and Scope

Alopecia is the medical designation for any partial or complete loss of hair from the scalp or other body regions where hair normally grows. The AAD distinguishes between scarring alopecia (cicatricial), in which the hair follicle is permanently destroyed, and non-scarring alopecia, in which the follicle remains structurally viable and regrowth is possible under appropriate conditions.

The scope of the condition is substantial. Androgenetic alopecia — the most prevalent subtype — affects approximately 50% of men by age 50 and up to 40% of women by age 70, according to AAD prevalence data. Alopecia areata, an autoimmune form, has an estimated lifetime prevalence of 2% in the United States (National Alopecia Areata Foundation). Telogen effluvium, a diffuse shedding disorder triggered by physiological stressors, is among the most frequent causes of sudden hair loss presenting to dermatology clinics.

From a regulatory standpoint, treatments for hair loss are governed by the U.S. Food and Drug Administration (FDA). As of this writing, the FDA has cleared minoxidil (topical and oral formulations) and finasteride (oral) as approved pharmacological agents for androgenetic alopecia, and has also approved baricitinib and ritlecitinib — both JAK inhibitors — for severe alopecia areata, representing the first FDA-approved systemic treatments for that specific indication.

Core Mechanics or Structure

Hair growth follows a cyclical biological program consisting of three primary phases. The anagen (growth) phase, during which the follicle actively produces the hair shaft, lasts 2 to 7 years in scalp hair and accounts for approximately 85–90% of all scalp hairs at any given time. The catagen (transition) phase lasts roughly 2 to 3 weeks, marking follicular regression. The telogen (resting) phase spans approximately 3 months, after which the hair is shed and the cycle restarts.

Disruption at any phase produces clinically observable shedding. In androgenetic alopecia, progressive miniaturization of follicles — driven by dihydrotestosterone (DHT) binding to androgen receptors within the follicle — shortens the anagen phase across successive cycles until the follicle produces only vellus (fine, unpigmented) hair. In alopecia areata, autoreactive T-lymphocytes breach the immune privilege of the hair follicle bulb, triggering anagen-phase arrest without follicle destruction. In telogen effluvium, a systemic physiological insult causes a premature, synchronized shift of follicles from anagen to telogen, producing diffuse shedding 2 to 4 months after the triggering event.

The structural integrity of the follicle determines whether the hair loss is reversible. Scarring alopecias — including lichen planopilaris and discoid lupus erythematosus involving the scalp — replace follicular units with fibrous tissue, eliminating regenerative potential.

Causal Relationships or Drivers

Hair loss arises from six major causal categories recognized in dermatological classification:

1. Genetic/Androgenic: Polygenic inheritance governs androgenetic alopecia susceptibility. The androgen receptor gene (AR) on the X chromosome contributes significantly to male pattern baldness risk, explaining the historically observed maternal inheritance pattern, though autosomal loci also contribute substantially.

2. Autoimmune: Alopecia areata, alopecia totalis (complete scalp hair loss), and alopecia universalis (total body hair loss) represent an autoimmune spectrum. Genome-wide association studies published in Nature Genetics have identified over 14 susceptibility loci, including regions overlapping with other autoimmune conditions such as rheumatoid arthritis and type 1 diabetes.

3. Hormonal and Endocrine: Thyroid dysfunction (both hypothyroidism and hyperthyroidism), polycystic ovary syndrome (PCOS), and postpartum hormonal shifts are established triggers of diffuse hair loss. Iron deficiency — even in the absence of frank anemia — has been associated with telogen effluvium in clinical studies published in the Journal of the American Academy of Dermatology (JAAD).

4. Nutritional: Deficiencies in zinc, biotin, protein, and vitamins D and B12 can impair normal hair cycling. Crash dieting producing caloric restriction below 1,000 calories per day has been documented as a precipitant of telogen effluvium.

5. Medication-Induced: Chemotherapy agents, anticoagulants (including heparin and warfarin), retinoids, beta-blockers, and certain antidepressants are documented causes of drug-induced alopecia. The FDA's MedWatch database classifies drug-induced hair loss by mechanism — anagen effluvium (chemotherapy-associated) versus telogen effluvium (most other drug classes).

6. Inflammatory and Infectious: Tinea capitis (scalp ringworm), caused by dermatophyte fungi, is a major cause of hair loss in children. Chronic inflammatory scalp conditions — seborrheic dermatitis, psoriasis — can contribute to hair shedding when poorly controlled. Occupational exposures to chemicals or physical agents are categorized under occupational skin conditions in clinical dermatology contexts.

Classification Boundaries

The primary taxonomic division in clinical alopecia is scarring vs. non-scarring, as this determines the ceiling on therapeutic outcomes. Within each category, further classification guides management:

Non-Scarring Alopecias
- Androgenetic alopecia (male and female pattern)
- Alopecia areata spectrum (patchy, totalis, universalis, ophiasis pattern)
- Telogen effluvium (acute and chronic)
- Anagen effluvium (chemotherapy or toxic exposure)
- Traction alopecia (mechanical, potentially progressive to scarring if prolonged)
- Trichotillomania (compulsive hair pulling, classified as an obsessive-compulsive spectrum disorder in DSM-5)

Scarring (Cicatricial) Alopecias
- Lichen planopilaris (LPP) and its variant, frontal fibrosing alopecia (FFA)
- Discoid lupus erythematosus of the scalp
- Folliculitis decalvans
- Dissecting cellulitis of the scalp
- Central centrifugal cicatricial alopecia (CCCA), disproportionately prevalent in Black women

The North American Hair Research Society (NAHRS) has published classification frameworks for cicatricial alopecias that distinguish primary (follicle is the target of inflammation) from secondary (follicle is destroyed as collateral damage to another process) forms.

Tradeoffs and Tensions

Diagnosis vs. Empirical Treatment: Scalp biopsy is the definitive method for distinguishing early scarring alopecia from non-scarring forms, yet biopsies are invasive, require correct site selection, and are underutilized in primary care. Delayed biopsy in cases of LPP or CCCA can result in irreversible follicle loss during the diagnostic workup period.

Finasteride in Women: Finasteride is FDA-approved only for men. Its use in premenopausal women is contraindicated due to teratogenic risk (FDA Pregnancy Category X under the old system). Dermatologists treating female pattern hair loss with finasteride off-label must navigate both efficacy uncertainty and significant regulatory and safety constraints.

JAK Inhibitor Benefit vs. Risk: The FDA approval of baricitinib and ritlecitinib for alopecia areata introduced the first systemic disease-modifying options for severe cases. However, JAK inhibitors carry an FDA Boxed Warning — the agency's highest-level safety designation — for risks including serious infections, malignancy, and cardiovascular events, creating a genuine benefit-risk tension for a condition that is not life-threatening.

Cosmetic vs. Medical Classification: Hair loss treatments occupying the cosmetic-medical boundary — including low-level laser therapy (LLLT) devices — are regulated by the FDA as Class II medical devices under 510(k) clearance rather than drug approval pathways, producing inconsistent evidentiary standards across treatment categories. The cosmetic vs. medical dermatology distinction carries concrete regulatory and insurance coverage implications.

Platelet-Rich Plasma (PRP): PRP injections for hair loss are widely marketed but not FDA-approved for this indication. Evidence quality in the peer-reviewed literature remains heterogeneous as of published systematic reviews in JAAD, creating tension between patient demand and evidence-based practice standards.

Common Misconceptions

Misconception: Hair loss is always hereditary.
Correction: Genetic androgenetic alopecia is the most common single cause, but thyroid disease, iron deficiency, fungal infection, medication effects, and autoimmune processes account for a substantial share of clinical presentations. Laboratory workup is standard practice before attributing hair loss solely to genetics.

Misconception: Frequent shampooing or hat-wearing causes permanent hair loss.
Correction: Neither practice destroys hair follicles. Shed hairs visible after washing are already in or near the telogen phase; the act of washing does not accelerate follicle cycling. Tight headwear worn chronically can contribute to traction alopecia, but casual hat use does not.

Misconception: Hair loss is exclusively a male condition.
Correction: Female pattern hair loss (FPHL) follows a distinct distribution (diffuse crown thinning rather than hairline recession) and affects tens of millions of women in the United States. FPHL is a named diagnostic entity in the AAD clinical guidelines.

Misconception: Biotin supplements reliably reverse hair loss.
Correction: Biotin deficiency is rare in adults consuming a varied diet. The FDA issued a 2019 safety communication warning that high-dose biotin supplementation can interfere with thyroid function tests and troponin assays, creating diagnostic confusion. Evidence supporting biotin supplementation for hair loss in the absence of confirmed deficiency is not established in controlled trials.

Misconception: Once hair follicles are gone, hair can always be restored with the right product.
Correction: Scarring alopecias cause permanent follicular destruction. No approved topical, oral, or device-based treatment restores hair in areas of established scarring. Surgical hair transplantation can relocate donor follicles from unaffected zones but cannot regenerate destroyed ones in situ.

Checklist or Steps (Non-Advisory)

The following sequence reflects standard clinical evaluation steps documented in AAD guidelines for the workup of hair loss. This is a reference framework, not individual medical guidance.

Step 1 — History Documentation
- Duration and pattern of shedding (acute vs. chronic; diffuse vs. focal)
- Family history of hair loss
- Medication list, including supplements and over-the-counter products
- Recent stressors: surgery, illness, childbirth, dietary changes (within the prior 3–6 months)
- Hair care practices and chemical or heat exposure history

Step 2 — Physical Examination
- Scalp inspection under good lighting; dermoscopy (trichoscopy) to assess follicular unit density and inflammation markers
- Pull test: gentle traction on a bundle of approximately 60 hairs to quantify telogen-phase shedding
- Assessment of hair shaft caliber and miniaturization pattern
- Skin and nail examination for systemic disease signs (nail pitting, scalp scaling, body hair involvement)

Step 3 — Laboratory Workup (Commonly Ordered)
- Complete blood count (CBC)
- Thyroid-stimulating hormone (TSH)
- Serum ferritin (iron stores)
- Total testosterone and DHEA-S (in women with signs of hyperandrogenism)
- Vitamin D 25-OH level
- ANA (antinuclear antibody) when autoimmune etiology is suspected

Step 4 — Dermoscopic/Trichoscopic Assessment
- Trichoscopy is now considered standard in academic dermatology centers for non-invasive follicular assessment; the dermoscopy and skin imaging reference covers this technique in detail

Step 5 — Scalp Biopsy (When Indicated)
- 4mm punch biopsy from an active lesion margin in suspected cicatricial alopecia
- Horizontal sectioning preferred by most hair pathologists for follicular unit counting
- Pathology interpreted in the context of clinical and trichoscopic findings

Step 6 — Diagnosis and Classification
- Assign to scarring or non-scarring category
- Identify specific subtype per NAHRS or AAD classification criteria
- Stage severity using validated scales: Hamilton-Norwood scale (male pattern), Ludwig scale (female pattern), SALT score (Severity of Alopecia Tool, for alopecia areata)

Reference Table or Matrix

For readers seeking a broader foundation in dermatological care across conditions, the National Dermatology Authority home page provides an entry point to the full clinical reference library, including the skin conditions overview and condition-specific resources.

References

• American Academy of Dermatology (AAD) — Hair Loss Resource Center
• [U.S. Food and Drug Administration (FDA) — Drug Approvals and Databases](https://www.fda.gov/drugs/

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)